Gland Pharma moves up on getting USFDA`s tentative nod for Angiotensin Injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Gland Pharma is currently trading at Rs. 1627.35, up by 9.40 points or 0.58% from its previous closing of Rs. 1617.95 on the BSE.
The scrip opened at Rs. 1610.05 and has touched a high and low of Rs. 1655.80 and Rs. 1610.05 respectively. So far 7881 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1914.00 on 29-Nov-2022 and a 52 week low of Rs. 861.50 on 22-May-2023.
Last one week high and low of the scrip stood at Rs. 1655.80 and Rs. 1597.05 respectively. The current market cap of the company is Rs. 26816.77 crore.
The promoters holding in the company stood at 57.86%, while Institutions and Non-Institutions held 27.36% and 14.78% respectively.
Gland Pharma has received tentative approval from the United States Food and Drug Administration (USFDA) for Angiotensin II Injection, 2.5 mg/mL Single Dose Vial. The company will launch the product with its marketing partner on receipt of final approval. The Angiotensin II Injection, 2.5 mg/mL Single Dose Vial (RLD: Giapreza Injection) has US sales of approximately $38 million for twelve months ending in September 2023, according to IQVIA.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.
